Lonza Strengthens Rapid Microbiology Portfolio With Planned Acquisition of Redberry

Lonza has announced that it has signed an agreement to acquire Redberry SAS, a company known for its rapid microbiology testing solutions powered by solid-phase cytometry (SPC). The move will expand Lonza’s bioscience testing capabilities and add the Red One system, a platform designed for rapid sterility and bioburden testing, to its growing suite of automated pharmaceutical quality control tools.

Redberry has established itself as a leader in SPC technology, offering highly sensitive and precise microbial detection solutions for the pharmaceutical sector. Its Red One platform is engineered to meet the industry’s increasing need for speed and simplicity in microbiological testing. The system delivers rapid sterility and bioburden results, with strong potential to streamline QC workflows.

In April 2025, Redberry announced the successful validation of its Red One rapid sterility testing method, which can generate results in just four days. Traditional sterility testing typically requires a minimum incubation period of 14 days, making Redberry’s approach a notable advancement for manufacturers seeking faster product release without compromising safety or compliance.

Lonza already provides a wide portfolio of QC testing services, including industry-leading endotoxin detection. The acquisition will integrate Redberry’s rapid detection technology into Lonza’s global offering, helping customers bring products to market more quickly while maintaining rigorous quality standards, especially in biologics and cell and gene therapy manufacturing.

Mike Goetter, Head of Bioscience, Specialized Modalities at Lonza, said: “Our agreement to acquire Redberry marks a significant milestone in our commitment to advancing QC microbiology solutions in line with growing industry demand for rapid testing platforms. By integrating this cutting-edge technology into our portfolio, we are empowering customers with faster and simpler tools that lower compliance costs. It will also support scale-up, process, and product integrity for biologics and cell and gene therapy production. It is a strategic step forward in reducing risk, ensuring right first time delivery, and enhancing efficiency across the industry.”

Jonathan Macron, CEO of Redberry, said: "Joining Lonza is a natural next step in Redberry’s journey. Since its creation, Redberry has been dedicated to delivering faster, simpler, and reliable microbiological control. By combining Red One™ with Lonza’s global reach and expertise, we will scale our innovation to meet the growing needs of pharmaceutical and industrial manufacturers, accelerate product release and benefit patients worldwide, while together setting a new standard in pharmaceutical quality control."

The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, and is not considered financially material to Lonza’s financial guidance.